CSL Behring - 716297 - 09/09/2025
The FDA addressed a matter regarding advertising and promotional labeling for biological products involving CSL Behring. The communication is categorized under regulatory oversight of drug and biological product promotion.
This affects CSL Behring and its internal departments responsible for regulatory affairs, promotional review, and biological product labeling compliance.
The source suggests an enforcement or advisory action specifically targeting promotional materials rather than clinical safety or manufacturing. This indicates that the FDA is monitoring the accuracy and consistency of claims made by biological product manufacturers to ensure they do not deviate from approved labeling or include misleading information.
Regulatory and compliance teams should audit current promotional materials to ensure alignment with approved labeling and FDA advertising standards. Internal reviewers must verify that all biological product claims are supported by sufficient evidence as defined by the agency.
Advertising & Promotional Labeling/Drugs/Biological Products
Open in openFDA / FDA.gov